Potential risks of pharmacy compounding

Drugs in R and D

Volumn 13, Issue 1, 2013, Pages 1-8

  Gudeman, Jennifer ^a   Jozwiakowski, Michael ^a   Chollet, John ^a   Randell, Michael ^b  

^a Ther Rx Corporation   (United States)

^b NORTHSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; BEVACIZUMAB; COLCHICINE; METHYLPREDNISOLONE ACETATE;

BACTERIAL MENINGITIS; CLINICAL PRACTICE; DRUG FORMULATION; DRUG QUALITY; EYE INFECTION; FOOD AND DRUG ADMINISTRATION; FUNGAL MENINGITIS; HUMAN; INFECTION RISK; PHARMACY; PRIORITY JOURNAL; RETINA MACULA DEGENERATION; REVIEW; SCIENTIFIC LITERATURE;

DRUG COMPOUNDING; HUMANS; PHARMACEUTICAL PREPARATIONS; RISK FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84876253343     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-013-0005-9     Document Type: Review

References (59)

1. Galson SK. Federal and State Role in Pharmacy Compounding and Reconstitution: Exploring the Right Mix to Protect Patients. Hearing on Oversight Before the Senate Comm. on Health, Education, Labor, & Pensions, 108th Cong. 2003. http://www.fda.gov/NewsEvents/Testimony/ucm115010.htm. Accessed Sept 2012.
2. United States Food and Drug Administration. The special risks of pharmacy compounding. 2012. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm107836. htm. Accessed Sept 2012.
3. Sellers S, Utian WH. Pharmacy compounding primer for physicians: prescriber beware. Drugs. 2012;72(16):2043-50.
4. Information Update on 17a-Hydroxyprogesterone Caproate (17P) from The American College of Obstetricians and Gynecologists and The Society for Maternal-Fetal Medicine - 13 October 2011. http://www.acog.org/~/media/ Announcements/20111013MakenaLtr.pdf. Accessed Apr 2012.
5. Wilson LE, Blythe D, Sharfstein JM. Fungal meningitis from injection of contaminated steroids: a compounding problem. JAMA. 2012;308(23):2461-2.
6. United States Food and Drug Administration. CFR - Code of Federal Regulations Title 21: Part 211 Current Good Manufacturing Practice for Finished Pharmaceuticals. 2012. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/ CFRSearch.cfm?CFRPart=211. Accessed Aug 2012.
7. National Association of Boards of Pharmacy. Model Pharmacy Act/Rules. 2012. http://www.nabp.net/government-affairs/model-pharmacy-act-rules. Accessed Jan 2013.
8. Boodoo JM. Compounding problems and compounding confusion: federal regulation of compounded drug products and the FDAMA circuit split. Am J Law Med. 2010;36(1):220-47.
9. United States Food and Drug Administration. FDA Talk Paper: FDA Warns Against Women Using Unapproved Drug, Domperidone, to Increase Milk Production. 2004. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm173886.htm. Accessed July 2012.
10. United States Food and Drug Administration. Updated FDA Statement on Compounded Versions of hydroxyprogesterone caproate (the active ingredient in Makena). 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm308546.htm. Accessed July 2012.
11. Draper R. The Toxic Pharmacist. 2003. http://www.nytimes.com/2003/06/08/ magazine/the-toxic-pharmacist.html?pagewanted=all&src=pm. Accessed July 2012.
12. Kastango E. Quality-control analytical methods: USP chapter 797 compounded sterile preparations sterility requirements and their relationship to beyond-use dating. Int J Pharm Compd. 2004;8(5):393-7.
13. Pharmaceutical compounding - sterile preparations (general chapter 797). United States Pharmacopeia 35 - National Formulary 30. Rockville: United States Pharmacopeial Convention; 2012.
14. Sterility Tests (general chapter 71). United States Pharmacopeia 35 - National Formulary 30. Rockville: United States Pharmacopeial Convention; 2012.
15. National Association of Boards of Pharmacy Model Pharmacy Act/Rules Page 207. 2012. http://www.nabp.net/government-affairs/model-actrules/. Accessed Apr 2012.
16. Texas State Board of Pharmacy, Business Meeting Minutes, February 9-10, 2010, Proposal of Rules, Rules Concerning Use of Sterile Gloves and Sterile Alcohol in Pharmacies Compounding Sterile Preparations (§291.133]. 2010. http://www.tsbp.state.tx.us/files-pdf/min2-2010.pdf. Accessed Nov 2012.
17. United States Food and Drug Administration. Meds IV pharmacy, IV compounded products recall: outbreak of Serratia marcescens bacteremia in Alabama hospitals. March 30, 2011. 2011. http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm249099.htm. Accessed Aug 2012.
18. Tainted TPN Cases Put Focus on 797 Rules, Pharmacy Practice News, June 2011, Volume 38. 2011. http://issuu.com/mcmahongroup/docs/ppn0611-de. Accessed Nov 2012.
19. Institute for Safe Medical Practices Safety Alert. TPN-related deaths call for FDA guidance and pharmacy board oversight of USP chapter 797. 2011. http://www.ismp.org/newsletters/acutecare/articles/20110407.asp. Accessed July 2012.
20. Fricker MP, Trissel LA, Rich DS. Turning a new chapter on IV drug compounding safety: USP/NF chapter 797. Hosp Pharm. 2004;9:899-920.
21. ACOG Committee opinion no. 532: compounded bioidentical menopausal hormone therapy. Obstet Gynecol. 2012;120(2 Pt 1):411-5.
22. Newton D, Trissel L. A primer on USP chapter 797 "pharmaceutical compounding - sterile preparations", and USP process for drug and practice standards. Int J Pharm Compd. 2004;8(4):251-63.
23. Health Canada: Health Products and Food Branch Inspectorate. Policy on manufacturing and compounding drug products in Canada POL-0051. 2009. http://www.hc-sc.gc.ca/dhp-mps/alt-formats/hpfb-dgpsa/pdf/compli-conform/ pol-0051-eng.pdf. Accessed Jan 2013.
24. United States Food and Drug Administration. Limited FDA Survey of Compounded Drug Products. 2001. http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm155725.htm. Accessed Mar 2013.
25. US Food and Drug Administration. Pharmacy Compounding. 2006 Limited FDA Survey of Compounded Drug Products. 2012. http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm204237.htm. Accessed Sept 2012.
26. Missouri Board of Pharmacy Compounding Report. FY2006-2009. http://pr.mo.gov/pharmacists-compounding.asp. Accessed Mar 2013.
27. Sasich LD, Sukkari SR. Unknown risks of pharmacy-compounded drugs. J Am Osteopath Assoc. 2008;108(2):86.
28. Texas State Board of Pharmacy, Business Meeting Minutes, November 9, 2010, Report on TSBP Sampling of Compounded Products, Tab 24. 2010. http://www.tsbp.state.tx.us/files-pdf/BN/Nov10/Additions/Tab24- Compounded%20Sample%20Testing.pdf. Accessed Nov 2012.
29. Azarnoff DL, Lee JC, Lee C, et al. Quality of extemporaneously compounded nitroglycerin ointment. Dis Colon Rectum. 2007;50(4):509-16.
30. Green DM, Jones AC, Brain KR. Content variability of active drug substance in compounded oral 3,4-diaminopyridine products. J Clin Pharm Ther. 2012;37(1):53-7.
31. Goldman MP. Sodium tetradecyl sulfate for sclerotherapy treatment of veins: is compounding pharmacy solution safe? Dermatol Surg. 2004;30(12 Pt 1):1454-6; discussion 1456.
32. Mahaguna V, McDermott JM, Zhang F, et al. Investigation of product quality between extemporaneously compounded progesterone vaginal suppositories and an approved progesterone vaginal gel. Drug Dev Ind Pharm. 2004;30(10):1069-78.
33. Chollet JL, Jozwiakowski MJ. Quality investigation of hydroxyprogesterone caproate active pharmaceutical ingredient and injection. Drug Dev Ind Pharm. 2012;38(5):540-9.
34. United States Food and Drug Adminstration. Questions and Answers on Updated FDA Statement on Compounded Versions of hydroxyprogesterone caproate (the active ingredient in Makena). 2012. http://www.fda.gov/newsevents/newsroom/ pressannouncements/ucm310215.htm. Accessed Mar 2013.
35. Heinrich J. GAO testimony: Federal and State Role in Pharmacy Compounding and Reconstitution: Exploring the Right Mix to Protect Patients: Hearing on Oversight Before the Senate Comm. on Health, Education, Labor, & Pensions, 108th Cong. 2003. http://gao.gov/assets/120/110456.pdf. Accessed Mar 2013.
36. Civen R, Vugia DJ, Alexander R, et al. Outbreak of Serratia marcescens infections following injection of betamethasone compounded at a community pharmacy. Clin Infect Dis Off Publ Infect Dis Soc Am. 2006;43(7):831-7.
37. Kato Z, Nakamura M, Yamagishi Y, et al. Pediatric thioridazine poisoning as a result of a pharmacy compounding error. Pediatr Rep. 2009;1(1):e9.
38. Romano MJ, Dinh A. A 1000-fold overdose of clonidine caused by a compounding error in a 5-year-old child with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108(2):471-2.
39. Sunenshine R, Schultz M, Lawrence MG, et al. An outbreak of postoperative gram-negative bacterial endophthalmitis associated with contaminated trypan blue ophthalmic solution. Clin Infect Dis Off Publ Infect Dis Soc Am. 2009;48(11):1580-3.
40. Suchard JR, Graeme KA. Pediatric clonidine poisoning as a result of pharmacy compounding error. Pediatr Emerg Care. 2002;18(4):295-6.
41. Gershman MD, Kennedy DJ, Noble-Wang J, et al. Multistate outbreak of Pseudomonas fluorescens bloodstream infection after exposure to contaminated heparinized saline flush prepared by a compounding pharmacy. Clin Infect Dis Off Publ Infect Dis Soc Am. 2008;47(11):1372-9.
42. Schwam E. Severe accidental overdose of 4-aminopyridine due to a compounding pharmacy error. J Emerg Med. 2011;41(1):51-4.
43. McCoy KS. Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome. N Engl J Med. 2007;357(22):2310-1.
44. Held MR, Begier EM, Beardsley DS, et al. Life-threatening sepsis caused by Burkholderia cepacia from contaminated intravenous flush solutions prepared by a compounding pharmacy in another state. Pediatrics. 2006;118(1):e212-5.
45. FDA Alerts Health Care Professionals of Infection Risk from Repackaged Avastin Intravitreal Injections. 2011. http://www.fda.gov/Drugs/DrugSafety/ ucm270296.htm. Accessed Mar 2013.
46. Exophiala infection from contaminated injectable steroids prepared by a compounding pharmacy - United States, July-November 2002. MMWR Morb Mortal Wkly Rep. 2002;51(49):1109-12.
47. Deaths from intravenous colchicine resulting from a compounding pharmacy error - Oregon and Washington, 2007. MMWR Morb Mortal Wkly Rep. 2007;56(40):1050-2.
48. Moberg-Wolff E. Potential clinical impact of compounded versus noncompounded intrathecal baclofen. Arch Phys Med Rehabil. 2009;90(11):1815-20.
49. Pollack A. Avastin injections are reported to cause blindness. 2011. http://www.nytimes.com/2011/08/31/health/31drug.html?ref=avastindrug. Accessed Mar 2013.
50. Pollack A. Five More Reports of Avastin Injections Causing Blindness. 2011. http://www.nytimes.com/2011/09/02/business/more-reports-of-avastin- causing-blindness.html?-r=1&ref=avastindrug. Accessed Mar 2013.
51. Centers for Disease Control and Prevention. Multistate Fungal Meningitis Outbreak Investigation: Laboratory Testing and Results from the Outbreak. 2012. http://www.cdc.gov/HAI/outbreaks/laboratory/lab-testing-results.html#labresults. Accessed Nov 2012.
52. Food and Drug Administration Inspectional Observations (Form 483) New England Compounding Center issued October 26th, 2012. 2012. http://www.fda.gov/ downloads/AboutFDA/CentersOffices/OfficeofGlobalRegulatoryOperationsandPolicy/ ORA/ORAElectronicReadingRoom/UCM325980.pdf. Accessed Nov 2012.
53. Kastango E. The cost of quality in pharmacy. Int J Pharm Compd. 2002;6(6):404-7.
54. Pharmacy Compounding Accreditation Board: PCAB™ Principles of Compounding. 2012. https://secure.pcab.info/about/downloads/principles-of- compounding.pdf. Accessed Sept 2012.
55. Mckenna KJ. Compounded sclerosing agents: risks and consequences. Vein Mag. 2008;1(2).
56. Patel Y, Rumore MM. Hydroxyprogesterone caproate injection (Makena) one year later: to compound or not to compound that is the question. P T. 2012;37(7):405-11.
57. Gallegos A. Physicians entangled in tainted drugs lawsuits. 2013. http://www.amednews.com/article/20130211/profession/130219977/2/. Accessed Mar 2013.
58. Compounding Pharmacies - What Every Retina Specialist Needs to Know. 2012. http://www.asrs.org/education/compounding-pharmacies-/background. Accessed Nov 2012.
59. Kabnick LS. Compounded Sclerosants And Foam: What Should You Know About This Controversial Area? Legal Guidelines for Use of Polidocanol and Sodium Tetradecyl Sulfate for Sclerotherapy. Veith Symposium; 19-23 Nov 2008; New York.